Stromal fibronectin expression in patients with resected pancreatic ductal adenocarcinoma
暂无分享,去创建一个
[1] R. Andersson,et al. Calcium-activated chloride channel regulator 1 as a prognostic biomarker in pancreatic ductal adenocarcinoma , 2018, BMC Cancer.
[2] M. Weniger,et al. The Extracellular Matrix and Pancreatic Cancer: A Complex Relationship , 2018, Cancers.
[3] J. Kleeff,et al. Therapeutic developments in pancreatic cancer: current and future perspectives , 2018, Nature Reviews Gastroenterology & Hepatology.
[4] A. Scope,et al. NKp46 Receptor‐Mediated Interferon‐&ggr; Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis , 2018, Immunity.
[5] H. Friess,et al. Pancreatic cancer: disease dynamics, tumor biology and the role of the microenvironment , 2018, Oncotarget.
[6] G. Marko‐Varga,et al. Proteomic analyses identify prognostic biomarkers for pancreatic ductal adenocarcinoma , 2018, Oncotarget.
[7] S. Richon,et al. Cancer-associated fibroblasts lead tumor invasion through integrin-β3–dependent fibronectin assembly , 2017, The Journal of cell biology.
[8] G. Long,et al. Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice , 2017, Current opinion in oncology.
[9] M. Büchler,et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial , 2017, The Lancet.
[10] R. Weinberg,et al. Emerging Biological Principles of Metastasis , 2017, Cell.
[11] R. Brekken,et al. Matrix control of pancreatic cancer: New insights into fibronectin signaling. , 2016, Cancer letters.
[12] R. Andersson,et al. The role of SPARC expression in pancreatic cancer progression and patient survival , 2015, Scandinavian journal of gastroenterology.
[13] G. von Heijne,et al. Tissue-based map of the human proteome , 2015, Science.
[14] J. Berlin,et al. A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors , 2014, Cancer Chemotherapy and Pharmacology.
[15] D. Figarella-Branger,et al. Fibronectin expression in glioblastomas promotes cell cohesion, collective invasion of basement membrane in vitro and orthotopic tumor growth in mice , 2014, Oncogene.
[16] Umar Mahmood,et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. , 2014, Cancer cell.
[17] Benjamin D. Smith,et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.
[18] R. Muschel,et al. The stromal compartments in pancreatic cancer: are there any therapeutic targets? , 2014, Cancer letters.
[19] S. Yamada,et al. Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer. , 2013, Surgery.
[20] S. Bender,et al. Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity. , 2010, Cancer research.
[21] Wei Liu,et al. The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. , 2008, Cancer research.
[22] M. Basik,et al. Tissue microarrays: emerging standard for biomarker validation. , 2008, Current opinion in biotechnology.
[23] R. Dubridge,et al. Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits , 2008, Investigational new drugs.
[24] R. Dubridge,et al. A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo , 2007, Journal of Translational Medicine.
[25] T. Khoury,et al. Epithelial-Mesenchymal Transition (EMT) and Activated Extracellular Signal-regulated Kinase (p-Erk) in Surgically Resected Pancreatic Cancer , 2007, Annals of Surgical Oncology.
[26] D G Altman,et al. REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British journal of cancer.
[27] R. Hruban,et al. Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways , 2005, Modern Pathology.
[28] K. Tsuchida,et al. Tumor-Stroma Interaction of Human Pancreatic Cancer: Acquired Resistance to Anticancer Drugs and Proliferation Regulation Is Dependent on Extracellular Matrix Proteins , 2004, Pancreas.
[29] R. Hruban,et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor–stromal interactions , 2003, Oncogene.
[30] Christine A Iacobuzio-Donahue,et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. , 2003, The American journal of pathology.
[31] Kenneth M. Yamada,et al. Fibronectin at a glance , 2002, Journal of Cell Science.
[32] S. Gansauge,et al. Altered expression of extracellular matrix molecules and their receptors in chronic pancreatitis and pancreatic adenocarcinoma in comparison with normal pancreas , 1995, International journal of pancreatology : official journal of the International Association of Pancreatology.
[33] A. Jemal,et al. Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.